

Resource Summary Report

Generated by T1D on Jul 29, 2026

PharmKGB

RRID:SCR_025580

Type: Tool

Proper Citation

PharmKGB (RRID:SCR_025580)

Resource Information

URL: <https://www.pharmgkb.org/>

Proper Citation: PharmKGB (RRID:SCR_025580)

Description: NIH-funded resource that provides information about how human genetic variation affects response to medications. PharmGKB collects, curates and disseminates knowledge about clinically actionable gene-drug associations and genotype-phenotype relationships.

Synonyms: Pharmacogenomics Knowledgebase

Resource Type: knowledge base, data or information resource

Keywords: human genetic variation affects, response to medications, clinically actionable gene-drug associations, genotype-phenotype relationships,

Funding: NIH

Availability: Free, Freely available,

Resource Name: PharmKGB

Resource ID: SCR_025580

Record Creation Time: 20240806T053245+0000

Record Last Update: 20260725T191504+0000

Ratings and Alerts

No rating or validation information has been found for PharmKGB.

No alerts have been found for PharmKGB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 104 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Wei S, et al. (2025) Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. *Frontiers in pharmacology*, 16, 1578033.

Wang Y, et al. (2025) Exploring the mechanism of the potential effects of Liujunzi Tang combined with Suanzaoren Tang in the treatment of lung cancer with insomnia based on network pharmacology and molecular docking technology. *Medicine*, 104(16), e42205.

Eawsakul K, et al. (2025) Evaluation of the antibacterial efficacy of combinations of *Garcinia mangostana*, *Curcuma comosa*, and *Acanthus ebracteatus* for acne vulgaris treatment: in Silico and in vitro validation. *BMC complementary medicine and therapies*, 25(1), 256.

Chen Z, et al. (2025) Impact of administration route and gene polymorphisms on the serum concentration of voriconazole among Chinese patients with hematologic malignancies. *Frontiers in pharmacology*, 16, 1445583.

Liu H, et al. (2025) Probing the molecular mechanism of kaempferol in relieving rheumatoid arthritis based on network pharmacology. *Scientific reports*, 15(1), 12645.

Han X, et al. (2025) Xifeng Jiannao pill mitigates MPTP-induced neuronal apoptosis by reducing inflammation and oxidative stress via MAPK signaling. *Metabolic brain disease*, 40(4), 170.

Mei X, et al. (2025) Systematic network pharmacology and experimental validation reveal anti-glioma mechanisms of *ganoderma lucidum* via multi-target regulation. *Discover oncology*, 16(1), 1467.

Wan Z, et al. (2025) Applications of Artificial Intelligence in Drug Repurposing. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(14), e2411325.

Hou L, et al. (2025) Exploring the mechanism of action of Lobetyolin in the treatment of allergic rhinitis based on network pharmacology and molecular docking. *Medicine*, 104(7), e41496.

Rim JH, et al. (2025) Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine. *Annals of laboratory medicine*, 45(2), 121.

Borb??n A, et al. (2025) Pharmacogenomics Tools for Precision Public Health and Lessons for Low- and Middle-Income Countries: A Scoping Review. *Pharmacogenomics and personalized medicine*, 18, 19.

Turon G, et al. (2025) Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa. *Nature communications*, 16(1), 9258.

Jia Y, et al. (2025) Astragalin attenuates caerulein-induced acute pancreatitis by targeting the NLRP3 signaling pathway and gut microbiota. *Bioresources and bioprocessing*, 12(1), 139.

Halman A, et al. (2025) Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy. *Clinical pharmacology and therapeutics*, 117(1), 106.

Zhang Y, et al. (2025) Exploring similarities and differences in anti-atherosclerotic potential bioactives among *Dendrobium* species by UPLC-Q-Exactive Orbitrap MS. *NPJ science of food*, 9(1), 6.

Zheng S, et al. (2025) Traditional Chinese Medicine for Liver Cancer Treatment: Network Pharmacology Research. *Current topics in medicinal chemistry*, 25(26), 3027.

Guo P, et al. (2025) Network Pharmacology to Unveil the Mechanism of Berberine in the Treatment of *Streptococcus suis* Meningitis in Humans and Pigs. *Toxics*, 13(2).

He G, et al. (2025) Network analysis and in vivo experiments reveal the therapeutic mechanisms of total ginsenosides in a *Drosophila* model of ulcerative colitis. *Frontiers in pharmacology*, 16, 1556579.

Mao X, et al. (2025) Integrative UHPLC-HRMS and computational biology reveal ferroptosis and anoikis targeting by Wenpitongluo decoction in cardiorenal syndrome. *Frontiers in chemistry*, 13, 1617676.

Cintawati YL, et al. (2025) Pharmacokinetic Profile of Isoniazid and Acetylator Status in Patients with Systemic Lupus Erythematosus: Implications for Tuberculosis Prevention Therapy in Indonesia. *Infection and drug resistance*, 18, 3637.